Technical success, clinical efficacy, and safety of endoscopic minor papilla interventions for symptomatic pancreatic diseases

Table 2 Primary and secondary outcomes of endoscopic minor papilla intervention for symptomatic pancreatic diseases (n = 43)

Outcomes	Value
Primary outcomes
Initial technical success of DCMP (n = 43)	32 (74.4)
Overall technical success (n = 43)	38 (88.4)1
Immediate clinical success (pain improvement; n = 43)	34 (79.1)2
OCP (n = 32)	26 (81.3)
Pancreas divisum (n = 8)	5 (62.5)
IPMN (n = 3)	3 (100.0)
Secondary outcomes
Long-term clinical success (n = 22)
Cumulative clinical success (%)
1-year	74.7
3-year	55.3
7-year	41.5
Pancreatic stone therapy (n = 16)
Complete success	7 (43.8)3
Partial success	2 (12.5)3
Unsuccess	7 (43.8)
Stenting bypass	3 (18.8)
EMP alone	1 (6.3)
Failed DCMP	3 (18.8)
Early adverse events (n = 43)	6 (14.0)
Post-ERCP pancreatitis	5 (11.5)4
Self-limited pancreatic duct bleeding	1 (2.3)
Late (> 6 months) adverse events (n = 22)5	2 (9.1)
Minor papilla stricture	1 (4.6)
Main pancreatic duct stricture	1 (4.5)

¹Additional free-hand needle knife precut minor papillotomy achieved technical success.

²Of the 9 patients with no pain improvement, 4 with unsuccessful deep cannulation and 5 received minor papilla endotherapy but failed to achieve > 50% improvement in abdominal pain.

³Clearance success of pancreatic stones was observed in 9 patients, 7 with complete success, and 2 with partial success.

⁴Including 1 severe and 4 mild post-endoscopic retrograde cholangiopancreatography

pancreatitis.

⁵Of the 34 patients with immediate clinical success after endoscopic minor papilla intervention procedures, 22 were followed up for a period of 57.5 (7-266) months.

Data are expressed as n (%) unless otherwise specified. DCMP: Deep cannulation via the minor papilla; ERCP: Endoscopic retrograde cholangiopancreatography; IPMN: Intraductal papillary mucinous neoplasm; OCP: Obstructive chronic pancreatitis.